Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?

Michelle R Ugolini-Lopes, Luciana Parente C Seguro, Maitê Xavier F Castro, Danielle Daffre, Alex C Lopes, Eduardo F Borba, Eloisa Bonfá, Michelle R Ugolini-Lopes, Luciana Parente C Seguro, Maitê Xavier F Castro, Danielle Daffre, Alex C Lopes, Eduardo F Borba, Eloisa Bonfá

Abstract

Objective: Two recent important lupus nephritis trials reported that proteinuria was a good predictor of renal outcome in Caucasians, but data on real-life situation, other races and severe nephritis are lacking to substantiate this finding as a simple test to guide clinical practice. The aim of this study was to validate proteinuria as a predictor of long-term renal outcome in real-life situation in a racially diverse group of patients with severe nephritis.

Methods: Proteinuria, serum creatinine (SCr) and urine red blood cells were assessed at baseline and after 3, 6 and 12 months, as early predictors of long-term renal outcome (SCr <1.5 mg/dL at 7 years), in 94 patients with biopsy-proven lupus nephritis. The parameter performance and cut-off values were computed by receiver operating characteristic curves. Kaplan-Meier curves were used to validate the parameter.

Results: A proteinuria <0.8 g/24 hours at 12 months was the best single predictor of long-term renal outcome (sensitivity 90%, specificity 78%, positive predictive value 67%, negative predictive value (NPV) 94% and area under the curve 0.86; p<0.001). Addition of other variables to proteinuria such as SCr and haematuria at 12 months did not improve its performance. The proteinuria cut-off value of 0.8 g/24 hours at 12 months was a good predictor of 7-year renal survival (years free of dialysis) for patients with pure membranous (p=0.005) and proliferative nephritis (p=0.043), as well as black (p=0.002) and white race (p=0.001), anti-dsDNA positive (p=0.001) and anti-dsDNA negative (p=0.04) and male (p=0.028) and female (p=0.003) patients.

Conclusion: We provided novel evidence that, in a real-life situation, proteinuria at 12 months of follow-up was the single best predictor of renal outcome at 7 years for an ethnically diverse group of patients with severe nephritis and a valid parameter for distinct histological classes, races, genders and anti-dsDNA profiles. The remarkably high NPV obtained reinforces its recommendation as the ideal predictor for clinical practice, since it is of low cost, easy to interpret, non-invasive and widely available.

Keywords: Lupus Nephritis; Outcome research; Proteinuria; Systemic Lupus Erythematosus.

Conflict of interest statement

Competing interests: EFB and EB received a grant from Conselho Nacional de Desenvolvimento Científico e Tecnológico (#307226/2014-0 to EFB and #305068/2014-8 to EB) not related with this work.

Figures

Figure 1
Figure 1
24-hour proteinuria (g/day) during follow-up in patients with good long-term renal outcome (SCr 

Figure 2

Receiver operating characteristic curves of…

Figure 2

Receiver operating characteristic curves of 24-hour proteinuria at 3 (A), 6 (B) and…

Figure 2
Receiver operating characteristic curves of 24-hour proteinuria at 3 (A), 6 (B) and 12 (C) months of follow-up. Area under the curve (AUC); the cut-off, sensitivity and specificity values and their CIs are shown in the graphs.

Figure 3

Renal survival Kaplan-Meier curves for…

Figure 3

Renal survival Kaplan-Meier curves for distinct histological classes, races, genders and anti-dsDNA profiles.…

Figure 3
Renal survival Kaplan-Meier curves for distinct histological classes, races, genders and anti-dsDNA profiles. The p values that are indicated above were calculated by log-rank tests.
Figure 2
Figure 2
Receiver operating characteristic curves of 24-hour proteinuria at 3 (A), 6 (B) and 12 (C) months of follow-up. Area under the curve (AUC); the cut-off, sensitivity and specificity values and their CIs are shown in the graphs.
Figure 3
Figure 3
Renal survival Kaplan-Meier curves for distinct histological classes, races, genders and anti-dsDNA profiles. The p values that are indicated above were calculated by log-rank tests.

References

    1. Majdan M. [Treat-to-target in rheumatology]. Wiad Lek 2015;68:259–64.
    1. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54:421–32.
    1. Bertsias GK, Tektonidou M, Amoura Z, et al. . Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771–82.
    1. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.
    1. Gordon C, Sutcliffe N, Skan J, et al. . Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42:1372–9.
    1. Klumb EM, Silva CA, Lanna CC, et al. . [Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis]. Rev Bras Reumatol 2015;55:1–21.
    1. Houssiau FA, Vasconcelos C, D'Cruz D, et al. . Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121–31.
    1. Appel GB, Contreras G, Dooley MA, et al. . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103–12.
    1. Furie R, Nicholls K, Cheng TT, et al. . Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379–89.
    1. ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 2014;66:3096–104.
    1. Corapi KM, Dooley MA, Pendergraft WF. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther 2015;17:110
    1. Dall'Era M, Cisternas MG, Smilek DE, et al. . Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015;67:1305–13.
    1. Tamirou F, Lauwerys BR, Dall'Era M, et al. . A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med 2015;2:e000123
    1. Oliveira-Santos M, Verani JF, Klumb EM, et al. . Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus 2011;20:320–9.
    1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
    1. Chen YE, Korbet SM, Katz RS, et al. . Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008;3:46–53.
    1. Contreras G, Lenz O, Pardo V, et al. . Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006;69:1846–51.
    1. Isenberg D, Appel GB, Contreras G, et al. . Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 2010;49:128–40.
    1. Collado MV, Dorado E, Rausch S, et al. . Long-term outcome of lupus nephritis class II in Argentine patients: an open retrospective analysis. J Clin Rheumatol 2016;22:299–306.
    1. Hanly JG, Su L, Urowitz MB, et al. . A longitudinal analysis of outcomes of lupus nephritis in an international inception cohort using a multistate model approach. Arthritis Rheumatol 2016;68:1932–44.
    1. Parikh SV, Nagaraja HN, Hebert L, et al. . Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol 2014;9:279–84.
    1. Korbet SM, Schwartz MM, Evans J, et al. . Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244–54.
    1. Austin HA, Muenz LR, Joyce KM, et al. . Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983;75:382–91.
    1. Appel GB, Cohen DJ, Pirani CL, et al. . Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987;83:877–85.
    1. Tesar V. Moderator's view: cyclophosphamide in lupus nephritis. Nephrol Dial Transplant 2016;31:1058–61.

Source: PubMed

3
Subscribe